Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

欧盟支持阿哌沙班治疗深静脉血栓形成和肺栓塞

2014-07-03 cath 编译 医学论坛网

阿哌沙班深静脉血栓形成肺栓塞
关注

欧洲药品管理局(EMA)人用药产品委员会(CHMP)支持阿哌沙班(apixaban)适应证的扩大，即用于深静脉血栓形成(DVT)和肺栓塞(PE)的治疗和预防。 CHMP的意见是基于AMPLIFY 试验结果和其延伸试验AMPLIFY-EXT的。在试验中，阿哌沙班与标准依诺肝素联合华法林在治疗急性静脉血栓栓塞方面同样有效，但服用阿哌沙班的患者严重出血并发症风险减少了69%。在一年期的延伸试验中，与安

欧洲药品管理局(EMA)人用药产品委员会(CHMP)支持阿哌沙班(apixaban)适应证的扩大，即用于深静脉血栓形成(DVT)和肺栓塞(PE)的治疗和预防。

CHMP的意见是基于AMPLIFY 试验结果和其延伸试验AMPLIFY-EXT的。在试验中，阿哌沙班与标准依诺肝素联合华法林在治疗急性静脉血栓栓塞方面同样有效，但服用阿哌沙班的患者严重出血并发症风险减少了69%。在一年期的延伸试验中，与安慰剂相比，服用阿哌沙班的患者静脉血栓栓塞发生率显著减少。

阿哌沙班是一种口服选择性Xa因子抑制剂，已在欧盟、美国、日本等国家获准用于减少非瓣膜性房颤患者卒中和系统性栓塞的风险;在美国和欧盟也已获准用于行择期髋关节或膝关节置换术患者的DVT预防。

其他新型口服抗凝药(包括利伐沙班和达比加群)也已获准用于DVT/PE的治疗分预防复发。

原始出处：


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697219, encodeId=ae88169e2198e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 01 05:33:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11258, encodeId=c3e411258fa, content=进入新型抗凝药的厮杀时代, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Sun Aug 24 17:31:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955200, encodeId=4913195520001, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 31 11:33:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483234, encodeId=7e8914832346e, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sat Jul 05 06:33:00 CST 2014, time=2014-07-05, status=1, ipAttribution=)]
    2014-10-01 fusion

    #静脉#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1697219, encodeId=ae88169e2198e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 01 05:33:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11258, encodeId=c3e411258fa, content=进入新型抗凝药的厮杀时代, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Sun Aug 24 17:31:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955200, encodeId=4913195520001, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 31 11:33:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483234, encodeId=7e8914832346e, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sat Jul 05 06:33:00 CST 2014, time=2014-07-05, status=1, ipAttribution=)]
    2014-08-24 rosa00tong

    进入新型抗凝药的厮杀时代

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1697219, encodeId=ae88169e2198e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 01 05:33:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11258, encodeId=c3e411258fa, content=进入新型抗凝药的厮杀时代, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Sun Aug 24 17:31:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955200, encodeId=4913195520001, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 31 11:33:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483234, encodeId=7e8914832346e, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sat Jul 05 06:33:00 CST 2014, time=2014-07-05, status=1, ipAttribution=)]
    2015-03-31 xue8602

    #静脉血#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1697219, encodeId=ae88169e2198e, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 01 05:33:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=11258, encodeId=c3e411258fa, content=进入新型抗凝药的厮杀时代, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=870092288, createdName=rosa00tong, createdTime=Sun Aug 24 17:31:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955200, encodeId=4913195520001, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Mar 31 11:33:00 CST 2015, time=2015-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483234, encodeId=7e8914832346e, content=<a href='/topic/show?id=c82e991e71b' target=_blank style='color:#2F92EE;'>#静脉血栓形成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99177, encryptionId=c82e991e71b, topicName=静脉血栓形成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d387907505, createdName=ms5187542471278033, createdTime=Sat Jul 05 06:33:00 CST 2014, time=2014-07-05, status=1, ipAttribution=)]
    2014-07-05 ms5187542471278033

    #静脉血栓形成#

    0

相关资讯

新一代口服抗凝新药艾乐妥®（阿哌沙班）获准在中国上市

由百时美施贵宝和辉瑞联合开发的抗凝新药艾乐妥 ?（ELIQUIS ?）（阿哌沙班）12日正式宣布在中国上市。艾乐妥 ?是新型的口服Xa因子抑制剂，用于髋关节或膝关节择期置换术的成年患者，预防静脉血栓栓塞症（VTE）。它的上市为临床上骨科手术后抗凝提供了安全有效的新选择，为中国髋/膝关节择期置换术的患者带来福音。 骨科大手术，如全髋关节或全膝关节置换术，是VTE发生的重要危险因素之一。术后患者如不

EHJ：阿哌沙班可降低房颤患者心血管病住院率

研究要点：阿哌沙班是一种新型的Xa因子抑制剂。研究表明阿哌沙班能降低房颤患者的心血管病住院率。房颤是临床实践中最常遇到的心脏节律紊乱，大量患者因房颤而住院治疗。阿哌沙班是一种新型的口服Xa因子抑制剂。最新的研究表明阿哌沙班能降低房颤患者心血管病住院率，相关结果发表在《欧洲心脏杂志》上。【原文下载】该研究是一项随机双盲临床试验，目的是评估对于不适合用维生素K拮抗剂治疗的房颤患者，服用阿哌沙班与阿司匹

NEJM：阿哌沙班治疗急性静脉血栓效果不劣于传统治疗（AMPLIFY研究）

静脉血栓是仅次于心肌梗死、中风的第三大常见血管病变致死原因。传统治疗包括使用注射抗凝药（如依诺肝素）5天，华法林治疗3个月。该方法尽管有效，但是肝素类药物需要皮下注射，且华法林治疗需要监控患者凝血功能并适时调整剂量。与此相比，阿派沙班作为口服抗凝药，或可简化静脉血栓的临床治疗。为此，研究人员在AMPLIFY研究中比较了阿派沙班与传统抗凝治疗对急性静脉血栓的临床效果。研究结果将发表在NEJM杂志上。

JACC：房颤复律患者抗凝：阿哌沙班PK华法林(ARISTOTLE研究)

房颤患者心脏复律后可能发生栓塞事件。对于房颤持续＜48小时的患者，当前指南推荐至少在心 脏复律前3周和复律后4周给予抗凝治疗，是INR维持在2.0-3.0。维生素K拮抗剂和达比加群或可降低复律后栓塞风险。那么，同为新型抗凝药的Xa因 子抑制剂阿哌沙班是否能够降低这种风险呢？阿哌沙班和华法林相比，哪个更好呢？为此，研究者对ARISTOTLE试验中复律患者的数据进行了事后分析，旨在确定房颤复律后服

阿哌沙班获批延迟的背后：拷问国内临床研究真实性

在ARISTOTLE决定性临床试验结果公布和发表后，许多人预期新型抗凝药阿哌沙班（Eliquis，辉瑞和百时美施贵宝）将会成为一个重磅炸弹。在经历了严格的审核之后，快速审批的希望破灭，阿哌沙班在FDA迟迟未获批准。最终该药的审批较原定的截止日期推迟了9个月，这是PDUFA日期延长和FDA完全回复函双重作用的结果。

华法林时代终结了吗?抗凝药如何选?

    去年12月28日，FDA批准阿哌沙班 （Eliquis，百时美施贵宝/辉瑞）用于非瓣膜性房颤（AF） 患者卒中和全身性栓塞的预防。随着多数大国批准阿哌沙班用于非瓣膜性心房颤动（AF）患者的卒中和系统性栓塞预防，现在，3种新口服抗凝药将全数用于该症，从而使医生在患者和药物的选择上无所适从。但是，这些药物真的会宣告华法林的终结吗？医生该如何决定选用哪种药呢？&nb

Baidu
map
Baidu
map
Baidu
map